

2023 Medicare Part D Information - IRA

Inflation Reduction Act

Effective **January 1, 2023**, the Inflation Reduction Act (IRA) requires Medicare Plan Sponsors to eliminate the deductible and impose a statutory maximum beneficiary cost-sharing of \$35 per one-month supply for Medicare Part D covered insulins. In addition, the IRA eliminates the deductible and imposes a \$0 cost-share for Medicare Part D covered adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP).

IMPORTANT: Pharmacies should be aware that the IRA provides Plan Sponsors a grace period of ninety (90) days through March 31, 2023, to implement the beneficiary cost-sharing maximum of \$35 per month for Medicare Part D covered insulins. As a result, Part D Enrollees may be temporarily required to pay a cost-share higher than the \$35 maximum per month for covered insulins through March 31, 2023. CVS Caremark® is prepared to implement the correct cost-sharing requirements for the IRA, however, there may be a small number of scenarios where Part D Enrollees may be charged a cost-share higher than the \$35 maximum per month for insulin claims.

INSULIN CLAIMS BETWEEN JANUARY 1, 2023, through MARCH 31, 2023

If a Part D Enrollee pays a cost-share higher than the \$35 monthly maximum on a Part D claim, please collect the appropriate cost-sharing from the Enrollee as returned in the pharmacy claims adjudication response in the Patient Pay Amount field (5Ø5-F5). The Plan Sponsor will refund the Part D Enrollee the difference between their Patient Pay Amount and the statutory IRA cost-sharing maximum within thirty (30) days from the point of service paid claim date.

PHARMACY ACTION REQUIRED:

- Collect the appropriate cost-share from the Part D Enrollee as returned in the claim response
- Pharmacies and Part D Enrollees do not need to take any further action
 - o Do <u>not</u> request Part D Enrollees submit receipts/claims to their Plan Sponsors for reimbursement.
 - Plan Sponsors will monitor for paid claim activity and will reimburse Part D Enrollees directly.

INSULIN CLAIMS AFTER APRIL 1, 2023

- Effective **April 1, 2023,** Medicare Part D covered insulins will no longer be in the grace period and should reflect the beneficiary cost-sharing maximum of \$35 per month.
- Effective July 1, 2023, Medicare Part B (e.g., Medicare Advantage, Medicare Part B FFS) covered
 insulins furnished through durable medical equipment (DME) such as an insulin pump will be subject to
 a \$35 maximum beneficiary cost sharing.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711 and/or fax the opt-out request to 401-652-0893, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvshealth.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt. An opt out request will not opt you out of purely informational, non-advertisements, Caremark pharmacy communications such as new implementation notices, formulary changes, point-of-sale issues, network enrollment forms, and amendments to the Provider Manual.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual, and as such is Caremark Confidential Information that must be protected by the Provider and used only as described in the Provider Manual.



PHARMACY ACTION REQUIRED:

• If a Part D Enrollee has questions related to an insulin in which they were charged a cost-share greater than \$35 per month after April 1, 2023, instruct the Part D Enrollee to contact their plan for more information.

ACIP VACCINES EFFECTIVE JANUARY 1, 2023

For ACIP-recommended adult vaccines, the Part D Enrollee cost-sharing should be \$0. For a list of the CVS Caremark ACIP-recommended Medicare Part D adult vaccines applicable to the IRA provisions, if covered through a Plan Sponsor's Formulary, please visit the CVS Caremark Pharmacy Portal at: **rxservices.cvscaremark.com.**

PHARMACY ACTION REQUIRED:

• If a Part D Enrollee has questions related to a vaccine in which they were charged a cost-share greater than \$0, instruct the Part D Enrollee to contact their plan for more information.

If you haven't already, please create a Pharmacy Portal account:

- Go to: rxservices.cvscaremark.com
- If you are an individual pharmacy and not already registered to use the Pharmacy Portal, click "Sign Up", complete the validation procedures, and create a user name and password.
- If you are a chain or PSAO headquarters and not already registered, contact your CVS Caremark Network Account Manager to receive login instructions.

To access communications and information regarding the 2023 Medicare Part D IRA requirements, click on the "Document Library" from the Home Page.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual, and as such is Caremark Confidential Information that must be protected by the Provider and used only as described in the Provider Manual.